[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:central-nervous-system-lymphoma":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":60,"states":61},"Central Nervous System Lymphoma",8,6,[8,16,22,28,35,41,47,54],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT07082868","A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL)",[12],"Phase 1","RECRUITING","2026-08-26T02:15:28.524219Z","2026-07-19T19:36:05.064133Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT06607549","Loncastuximab Tesirine and Rituximab Following Stereotactic Radiosurgery in Patients With Central Nervous System Lymphomas (SOLAR)",[12],"2026-08-26T02:18:42.501841Z","2026-05-05T02:43:27.286682Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":26,"content_modified":27},"NCT05625594","Intracerebroventricular Administration of CD19-CAR T Cells (CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn\u002FMem T-lymphocytes) for the Treatment of Central Nervous System Lymphoma",[12],"2026-08-26T02:18:43.501109Z","2026-05-05T02:43:27.177772Z",{"nct_id":29,"title":30,"phases":31,"status":13,"updated_at":33,"content_modified":34},"NCT04186520","CAR-20\u002F19-T Cells in Patients With Relapsed Refractory B Cell Malignancies",[32],"Phase 1\u002FPhase 2","2026-08-26T02:15:44.309045Z","2026-05-05T02:43:27.998949Z",{"nct_id":36,"title":37,"phases":38,"status":13,"updated_at":39,"content_modified":40},"NCT05011045","Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies",[],"2026-08-26T02:17:16.126291Z","2026-05-13T02:55:06.277713Z",{"nct_id":42,"title":43,"phases":44,"status":13,"updated_at":45,"content_modified":46},"NCT03375619","Long-term Follow-up Study of Patients Receiving CAR-T Cells",[],"2026-08-26T02:19:23.493898Z","2026-05-13T02:55:06.122685Z",{"nct_id":48,"title":49,"phases":50,"status":51,"updated_at":52,"content_modified":53},"NCT07608731","Golcadomide With Pemetrexed, Rituximab, and Dexamethasone for Relapsed and Refractory CNS Lymphomas",[12],"NOT_YET_RECRUITING","2026-08-26T02:19:28.327680Z","2026-05-29T15:36:40.226544Z",{"nct_id":55,"title":56,"phases":57,"status":51,"updated_at":58,"content_modified":59},"NCT07701889","Bispecific CD19\u002FCD20-Targeted Chimeric Antigen Receptor (CAR) Modified T Cells With 4-1BB and Mutated CD28 Costimulatory Domains in Patients With Relapsed or Refractory CD19+ Hematologic Malignancies",[12],"2026-08-26T02:19:01.741747Z","2026-07-19T19:36:05.085306Z",[],[]]